Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01660906 · ClinicalTrials.gov registry record · Phase 4

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

A Phase 4 study of Chronic Phase Chronic Myeloid Leukemia, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 4
Development phase
39
Enrollment target
20
Study locations

NCT01660906 is a Phase 4 study of Chronic Phase Chronic Myeloid Leukemia that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 39 participants. The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01660906, a Phase 4 study of Chronic Phase Chronic Myeloid Leukemia, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 4
Development phase
39 participants
Enrollment target
20
Study locations

Study Summary

This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.

Conditions Studied

Chronic Phase Chronic Myeloid Leukemia

Interventions

  • DRUG Dasatinib

Study Locations (20)

Other

  • Local Institution - Créteil
  • Local Institution - Lille
  • Local Institution - Pierre-Bénite
  • Local Institution - Pringy
  • Local Institution - Vandœuvre-lès-Nancy
  • Local Institution - Cologne
  • Local Institution - Jena
  • Local Institution - Lübeck
  • Local Institution - Mannheim
  • Local Institution - Rostock
  • Local Institution - Catania
  • Local Institution - Florence
  • Local Institution - Naples
  • Local Institution - Roma
  • Local Institution - Roma

California

  • Pacific Cancer Medical Center - Anaheim

Connecticut

  • Cancer Center Of Central Connecticut - Southington

Maryland

  • St. Agnes Healthcare, Inc. - Baltimore

Ohio

  • Promedica Hematology & Oncology Assoicates - Sylvania

Texas

  • The University Of Texas Md Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2012-12
Est. Completion 2015-10
Phase Phase 4

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01660906

The ClinicalTrials.gov registry entry for NCT01660906 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Phase Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Dasatinib is the first listed.

NCT01660906 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Connecticut.

Frequently Asked Questions

What is clinical trial NCT01660906 about?

NCT01660906 is a clinical study titled "Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib". This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.

What is the current status of trial NCT01660906?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2012-12. Estimated completion is 2015-10.

What conditions does trial NCT01660906 study?

This clinical trial studies the following conditions: Chronic Phase Chronic Myeloid Leukemia.

What interventions are being tested in trial NCT01660906?

The interventions under investigation include: Dasatinib (DRUG).

Who is sponsoring clinical trial NCT01660906?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01660906 being conducted?

This trial has 20 study locations across California, Connecticut, Maryland, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Phase Chronic Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Phase Chronic Myeloid Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.